AAPL 190.615 -3.2313% MSFT 356.3901 -3.0969% NVDA 95.26 -6.1385% GOOGL 146.34 -3.1887% GOOG 148.62 -3.0908% AMZN 165.59 -4.067% META 483.025 -3.6801% AVGO 161.805 -5.3717% LLY 809.03 -3.6823% TSLA 223.7399 -7.3042% TSM 147.28 -2.9392% V 318.115 -3.4875% JPM 227.27 -2.0219% UNH 430.0 -5.3093% NVO 58.005 -0.1291% WMT 91.56 -1.7807% LVMUY 107.85 -1.5428% XOM 104.42 -2.3382% LVMHF 538.5 -2.6221% MA 505.115 -2.3612%
Viking Therapeutics, Inc. (NASDAQ: VKTX)
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. As per our previous US Dailies report published on ‘VKTX’ on 31st Jan 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 33.94 based on technical analysis.
Noted below are the details of support and resistance levels provided in our previous report:
Xxxxxx Xxxxxx Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Enter your details below and our team will help you to decide if this product is best for you.
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
US
CA
NZ
UK
AU
IND
Please wait processing your request...